PPARA and ischemic cardiomyopathy: The overall aim of this study was to work on clinical answers to fight the progression of ischemic cardiomyopathy at an early phase and gain insight into the metabolic interaction of enhanced ECS and the PPAR-α-mediated pathomechanisms.